MedTrace Logo

iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations

NCT03728322 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-11-05

No results posted yet for this study

Summary

This is a single centre、single arm、open-label study，to investigate the safety and efficacy of the gene correction of HBB in patient-specific iHSCs using CRISPR/Cas9.

Conditions

Interventions

BIOLOGICAL

iHSCs treatment group

iHSCs intravenous injection

Sponsors & Collaborators

  • Allife Medical Science and Technology Co., Ltd.

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
2 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2020-01-31
Completion
2021-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03728322 on ClinicalTrials.gov